Enlivex Announces Third Quarter 2022 Financial Results and Provides a Business Update

Nes-Ziona, Israel, Dec. 05, 2022 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, on December 2, 2022 filed with the SEC its financial results and related management’s discussion for the third quarter ended September 30, 2022.

Read more at globenewswire.com